Omnicell's Q3 2022 GAAP revenues reached $348 million, a 17% increase from Q3 2021. GAAP net income was $17 million, or $0.37 per diluted share, compared to $29 million, or $0.61 per diluted share, in Q3 2021. The company experienced headwinds in point of care products due to capital budget freezes and labor challenges, but saw strong demand for Advanced Services and a record number of Central Pharmacy Dispensing Systems installations.
GAAP and non-GAAP revenues of $348 million.
GAAP net income per diluted share of $0.37.
Non-GAAP net income per diluted share of $1.00.
Experienced headwinds in point of care products due to health system capital budget freezes and customer labor availability challenges.
For Q4 2022, Omnicell expects total GAAP and non-GAAP revenues between $285 million and $295 million, GAAP and non-GAAP product revenues between $183 million and $188 million, GAAP and non-GAAP service revenues between $102 million and $107 million, non-GAAP EBITDA between $10 million and $16 million, and non-GAAP earnings between $0.05 and $0.15 per share.
Analyze how earnings announcements historically affect stock price performance